Advertisement

International Urology and Nephrology

, Volume 51, Issue 7, pp 1191–1197 | Cite as

Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease

  • Sultan OzkurtEmail author
  • Ibrahim Dogan
  • Oguzhan Ozcan
  • Nurdan Fidan
  • Ilter Bozaci
  • Behice Yilmaz
  • Muzaffer Bilgin
Nephrology - Original Paper

Abstract

Purpose

The decrease in kidney functions in autosomal dominant polycystic kidney disease (ADPKD) is strongly correlated with the severity and growth of kidney cysts. Total kidney volume (TKV) was shown to be an early marker of the severity of the disease and a predictor of reduction in kidney functions. New treatment approaches for ADPKD have led to a need for easily applicable strong biomarkers predicting progression of the disease. The profibrotic mediator of galectin-3 (Gal-3) is linked to development of renal fibrosis.

Methods

The study included 74 patients with ADPKD diagnosis and 40 healthy controls. The TKV of patients was calculated using the manual tracing method on MR images. The serum Gal-3 levels of patient and healthy control groups were measured with the ELISA method. The correlations between serum Gal-3 value with TKV and kidney function were assessed in patients.

Results

As the stage of chronic kidney disease (CKD) increased, serum Gal-3 and TKV values increased (p < 0.001, p = 0.049, respectively). Correlation analysis found a negative relationship between serum Gal-3 levels and eGFR (r: − 0.515, p < 0.001); however, there was no relationship between serum Gal-3 and TKV (r = 0.112, p = 0.344). Linear regression analysis showed the major parameter affecting Gal-3 was eGFR (p = 0.016).

Conclusions

In our study, we showed that renal impairment is an important determinant of Gal-3, and there is no correlation of Gal-3 and TKV in ADPKD. As a result, there is an urgent clinical need for new biomarkers to identify individuals with the chance of treatment in the early stage among ADPKD patients.

Keywords

Autosomal dominant polycystic kidney disease Fibrosis Galectin-3 Total kidney volume 

Notes

Funding

Supported by Eskisehir Osmangazi University Scientific Research Project. Project number: 2017-11044.

Compliance with ethical standards

Conflict of interest

There are no declared conflicts of interest in this study.

References

  1. 1.
    Spithoven EM, Kramer A, Meijer E et al (2014) Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA registry. Nephrol Dial Transplant 29:15–25CrossRefGoogle Scholar
  2. 2.
    Grantham JJ, Chapman AB, Torres VE (2006) Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 1:148–157CrossRefPubMedGoogle Scholar
  3. 3.
    Cornec-Le Gall E, Audrézet MP, Chen JM et al (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24:1006–1013CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Grantham JJ, Torres VE, Chapman AB et al (2006) Volume progression in polycystic kidney disease. N Engl J Med 354:2122–2130CrossRefPubMedGoogle Scholar
  5. 5.
    Chapman AB, Devuyst O, Eckardt KU et al (2015) Autosomal—dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88:17–27CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407–2418CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Magistroni R, Corsi C, Martí T, Torra R (2018) A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression. Am J Nephrol 48:67–78CrossRefPubMedGoogle Scholar
  8. 8.
    Chapman AB, Guay-Woodford LM, Grantham JJ et al (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 64:1035–1045CrossRefPubMedGoogle Scholar
  9. 9.
    Grantham JJ (2015) Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol 30:1053–1062CrossRefPubMedGoogle Scholar
  10. 10.
    Grantham JJ, Mulamalla S, Swenson-Fields KI (2011) Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7:556–566CrossRefPubMedGoogle Scholar
  11. 11.
    Dhirapong A, Lleo A, Leung P, Gershwin ME, Liu FT (2009) The immunological potential of galectin-1 and -3. Autoimmun Rev 8:360–363CrossRefPubMedGoogle Scholar
  12. 12.
    Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 203:160–171CrossRefGoogle Scholar
  13. 13.
    Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sharma UC, Pokharel S, van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128CrossRefPubMedGoogle Scholar
  15. 15.
    de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ (2009) Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11:811–817CrossRefPubMedGoogle Scholar
  16. 16.
    Lok DJ, Van Der Meer P, de la Porte PW et al (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure. Clin Res Cardiol 99:323–328CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lin YH, Lin LY, Wu YW et al (2009) The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96–99CrossRefPubMedGoogle Scholar
  18. 18.
    McCullough PA, Olobatoke A, Vanhecke TE (2011) Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 12:200–210PubMedGoogle Scholar
  19. 19.
    Grupper A, Nativi-Nicolau J, Maleszewski JJ et al (2016) Circulating galectin-3 levels are persistently elevated after heart transplantation and are associated with renal dysfunction. JACC Heart Fail 4:847–856CrossRefPubMedGoogle Scholar
  20. 20.
    Meijers WC, van der Velde AR, Ruifrok WP et al (2014) Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc 3:e000962CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gopal DM, Kommineni M, Ayalon N et al (2012) Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc 1:e000760CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    O’Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS (2013) Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 24:1880–1888CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bullock SL, Johnson TM, Bao Q, Hughes RC, Winyard PJ, Woolf AS (2001) Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J Am Soc Nephrol 12:515–523PubMedGoogle Scholar
  24. 24.
    Hikita C, Vijayakumar S, Takito J, Erdjument- Bromage H, Tempst P, Al-Awqati Q (2000) Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin 3. J Cell Biol 151:1235–1246CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Guay-Woodford LM, Desmond RA (2003) Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 111:1072–1080CrossRefPubMedGoogle Scholar
  26. 26.
    Bao Q, Hughes RC (1999) Galectin-3 and polarized growth within collagen gels of wild-type and ricin-resistant MDCK renal epithelial cells. Glycobiology 9:489–495CrossRefPubMedGoogle Scholar
  27. 27.
    Olsan EE, West JD, Torres JA, Doerr N, Weimbs T (2018) Identification of targets of IL-13 and STAT6 signaling in polycystic kidney disease. Am J Physiol Renal Physiol 1(315):86–96CrossRefGoogle Scholar
  28. 28.
    Fernandes Bertocchi AP, Campanhole G, Wang PH et al (2018) A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int 21:999–1007CrossRefGoogle Scholar
  29. 29.
    Nishiyama J, Kobayashi S, Ishida A et al (2000) Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol 157:815–823CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Vansthertem D, Cludts S, Nonclercq D et al (2010) Immunohistochemical localization of galectins-1 and -3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat. Histol Histopathol 25:1417–1429PubMedGoogle Scholar
  31. 31.
    Okamura DM, Pasichnyk K, Lopez-Guisa JM et al (2010) Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 300:245–253CrossRefGoogle Scholar
  32. 32.
    Kang EH, Moon KC, Lee EY et al (2009) Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 18:22–28CrossRefPubMedGoogle Scholar
  33. 33.
    Mann DL (1999) Inflammatory mediators in heart failure: homogeneity through heterogeneity. Lancet 353:1812–1813CrossRefPubMedGoogle Scholar
  34. 34.
    Dancer JY, Truong LD, Zhai Q, Shen SS (2010) Expression of galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med 134:90–94PubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Nephrology, Faculty of MedicineEskisehir Osmangazi UniversityOdunpazarıTurkey
  2. 2.Department of Nephrology, Faculty of MedicineHitit UniversityÇorumTurkey
  3. 3.Department of Biochemistry, Faculty of MedicineMustafa Kemal UniversityHatayTurkey
  4. 4.Department of Radiology, Faculty of MedicineHitit UniversityÇorumTurkey
  5. 5.Department of RadiologyHaseki Education and Research HospitalIstanbulTurkey
  6. 6.Department of Biostatistics, Faculty of MedicineEskisehir Osmangazi UniversityEskisehirTurkey

Personalised recommendations